These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 31923386)

  • 1. High-density lipoprotein cholesterol efflux capacity and cardiovascular risk in autoimmune and non-autoimmune diseases.
    Hafiane A; Favari E; Daskalopoulou SS; Vuilleumier N; Frias MA
    Metabolism; 2020 Mar; 104():154141. PubMed ID: 31923386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-density lipoprotein cholesterol efflux capacity is inversely associated with cardiovascular risk: a systematic review and meta-analysis.
    Qiu C; Zhao X; Zhou Q; Zhang Z
    Lipids Health Dis; 2017 Nov; 16(1):212. PubMed ID: 29126414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholesterol efflux capacity: An introduction for clinicians.
    Anastasius M; Kockx M; Jessup W; Sullivan D; Rye KA; Kritharides L
    Am Heart J; 2016 Oct; 180():54-63. PubMed ID: 27659883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High density lipoprotein proteome is associated with cardiovascular risk factors and atherosclerosis burden as evaluated by coronary CT angiography.
    Gordon SM; Chung JH; Playford MP; Dey AK; Sviridov D; Seifuddin F; Chen YC; Pirooznia M; Chen MY; Mehta NN; Remaley AT
    Atherosclerosis; 2018 Nov; 278():278-285. PubMed ID: 30347343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDL (High-Density Lipoprotein) Cholesterol Efflux Capacity Is Associated With Incident Cardiovascular Disease in the General Population.
    Ebtehaj S; Gruppen EG; Bakker SJL; Dullaart RPF; Tietge UJF
    Arterioscler Thromb Vasc Biol; 2019 Sep; 39(9):1874-1883. PubMed ID: 31315436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).
    Khera AV; Demler OV; Adelman SJ; Collins HL; Glynn RJ; Ridker PM; Rader DJ; Mora S
    Circulation; 2017 Jun; 135(25):2494-2504. PubMed ID: 28450350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HDL cholesterol efflux capacity and incident cardiovascular events.
    Rohatgi A; Khera A; Berry JD; Givens EG; Ayers CR; Wedin KE; Neeland IJ; Yuhanna IS; Rader DR; de Lemos JA; Shaul PW
    N Engl J Med; 2014 Dec; 371(25):2383-93. PubMed ID: 25404125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives.
    Adorni MP; Ronda N; Bernini F; Zimetti F
    Cells; 2021 Mar; 10(3):. PubMed ID: 33807918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adiponectin Predicts High-Density Lipoprotein Cholesterol Efflux Capacity in Adults Irrespective of Body Mass Index and Fat Distribution.
    Marsche G; Zelzer S; Meinitzer A; Kern S; Meissl S; Pregartner G; Weghuber D; Almer G; Mangge H
    J Clin Endocrinol Metab; 2017 Nov; 102(11):4117-4123. PubMed ID: 28938424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Environmental Factors Modifying HDL Functionality.
    Kosmas CE; Sourlas A; Guzman E; Kostara CE
    Curr Med Chem; 2022; 29(10):1687-1701. PubMed ID: 34269662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HDL Cholesterol Efflux Capacity: Cardiovascular Risk Factor and Potential Therapeutic Target.
    Bhatt A; Rohatgi A
    Curr Atheroscler Rep; 2016 Jan; 18(1):2. PubMed ID: 26710794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-density lipoprotein cholesterol efflux capacity is not associated with atherosclerosis and prevalence of cardiovascular outcome: The CODAM study.
    Josefs T; Wouters K; Tietge UJF; Annema W; Dullaart RPF; Vaisar T; Arts ICW; van der Kallen CJH; Stehouwer CDA; Schalkwijk CG; Goldberg IJ; Fisher EA; van Greevenbroek MMJ
    J Clin Lipidol; 2020; 14(1):122-132.e4. PubMed ID: 31791716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholesterol efflux and reverse cholesterol transport.
    Favari E; Chroni A; Tietge UJ; Zanotti I; Escolà-Gil JC; Bernini F
    Handb Exp Pharmacol; 2015; 224():181-206. PubMed ID: 25522988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extra Virgin Olive Oil Prevents the Age-Related Shifts of the Distribution of HDL Subclasses and Improves Their Functionality.
    Otrante A; Trigui A; Walha R; Berrougui H; Fulop T; Khalil A
    Nutrients; 2021 Jun; 13(7):. PubMed ID: 34209930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of HDL Cholesterol Removal Capacity: Toward Clinical Application.
    Toh R
    J Atheroscler Thromb; 2019 Feb; 26(2):111-120. PubMed ID: 30542002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-Density Lipoprotein Function Measurement in Human Studies: Focus on Cholesterol Efflux Capacity.
    Rohatgi A
    Prog Cardiovasc Dis; 2015; 58(1):32-40. PubMed ID: 25968932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses.
    van Capelleveen JC; Kastelein JJ; Zwinderman AH; van Deventer SJ; Collins HL; Adelman SJ; Round P; Ford J; Rader DJ; Hovingh GK
    J Clin Lipidol; 2016; 10(5):1137-1144.e3. PubMed ID: 27678430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammation, remodeling, and other factors affecting HDL cholesterol efflux.
    Ronsein GE; Vaisar T
    Curr Opin Lipidol; 2017 Feb; 28(1):52-59. PubMed ID: 27906712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients.
    Gille A; D'Andrea D; Tortorici MA; Hartel G; Wright SD
    Arterioscler Thromb Vasc Biol; 2018 Apr; 38(4):953-963. PubMed ID: 29437574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-Density Lipoprotein Functionality as a New Pharmacological Target on Cardiovascular Disease: Unifying Mechanism That Explains High-Density Lipoprotein Protection Toward the Progression of Atherosclerosis.
    Favari E; Thomas MJ; Sorci-Thomas MG
    J Cardiovasc Pharmacol; 2018 Jun; 71(6):325-331. PubMed ID: 29528874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.